Zlatopolskiy Boris D, Morgenroth Agnieszka, Urusova Elizaveta A, Dinger Cornelia, Kull Thomas, Pape Manuela, Glatting Gerhard, Reske Sven N
Klinik für Nuklearmedizin, Ulm University, Albert-Einstein-Allee 23, Ulm, Germany.
Bioorg Med Chem Lett. 2009 Sep 1;19(17):5151-4. doi: 10.1016/j.bmcl.2009.07.017. Epub 2009 Jul 9.
Three new potential hENT(1) inhibitors suitable for labeling with PET/SPECT radioisotopes were prepared from an advanced intermediate 4. They were tested for their capability to inhibit binding of SAENTA-fluorescein to HL60 leukemia cells in flow cytometry assay and SAENTA-I (5) was determined to be the most active compound. (131)I-5 showed high hENT(1)-specific binding (up to 54% ID) to 6 from 7 tested tumor cell lines and was chosen for further in vivo study.